
## Miranda Davies

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8593590/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Remdesivir in Treatment of COVID-19: A Systematic Benefit–Risk Assessment. Drug Safety, 2020, 43, 645-656.	3.2	54
2	Lopinavir-Ritonavir in the Treatment of COVID-19: A Dynamic Systematic Benefit-Risk Assessment. Drug Safety, 2020, 43, 809-821.	3.2	49
3	Safety Profile of Modafinil Across a Range of Prescribing Indications, Including Off-Label Use, in a Primary Care Setting in England. Drug Safety, 2013, 36, 237-246.	3.2	31
4	Safety Profile of Esomeprazole. Drug Safety, 2008, 31, 313-323.	3.2	18
5	Systematic benefit-risk assessment for buprenorphine implant: a semiquantitative method to support risk management. BMJ Evidence-Based Medicine, 2020, 25, 199-205.	3.5	10
6	Evaluation of the incidence of bleeding in patients prescribed rivaroxaban for the treatment and prevention of deep vein thrombosis and pulmonary embolism in UK secondary care: an observational cohort study. BMJ Open, 2020, 10, e038102.	1.9	9
7	How to Investigate a Serious Adverse Event Reported During a Clinical Trial for a COVID-19 Vaccine. Drug Safety, 2021, 44, 1-5.	3.2	7
8	Rationale and design of a European epidemiological post-authorization safety study (PASS) program: rivaroxaban use in routine clinical practice. Expert Opinion on Drug Safety, 2020, 19, 1513-1520.	2.4	5